clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Conjunctival Neoplasms D003230 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Cross Infection D003428 9 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Cysts D003560 4 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Drug Eruptions D003875 30 associated lipids
Dermatomycoses D003881 17 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Kunin M et al. Mycobacterium chelonae peritonitis in peritoneal dialysis. Literature review. 2014 Eur. J. Clin. Microbiol. Infect. Dis. pmid:24569948
Fan Y et al. High and low doses of clarithromycin treatment are associated with different clinical efficacies and immunomodulatory properties in chronic rhinosinusitis. 2014 J Laryngol Otol pmid:24555753
Hanson KE et al. Rapid molecular detection of inducible macrolide resistance in Mycobacterium chelonae and M. abscessus strains: a replacement for 14-day susceptibility testing? 2014 J. Clin. Microbiol. pmid:24554745
Almeida N et al. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study. 2014 Helicobacter pmid:24506175
Lara-Martín PA et al. Occurrence, distribution and partitioning of nonionic surfactants and pharmaceuticals in the urbanized Long Island Sound Estuary (NY). 2014 Mar. Pollut. Bull. pmid:24467856
Markert C et al. Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers. 2014 Br J Clin Pharmacol pmid:23738582
Furuta T et al. Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. 2014 J Clin Pharmacol pmid:24122836
Ratzinger F et al. Azithromycin suppresses CD4(+) T-cell activation by direct modulation of mTOR activity. 2014 Sci Rep pmid:25500904
Shahbazi Niaz M et al. Investigation into physical-chemical variables affecting the manufacture and dissolution of wet-milled clarithromycin nanoparticles. 2014 Pharm Dev Technol pmid:24093825
Trotti LM et al. Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience. 2014 J. Psychopharmacol. (Oxford) pmid:24306133
Negrín-González J et al. Psychiatric adverse reaction induced by clarithromycin. 2014 Eur Ann Allergy Clin Immunol pmid:24853570
Nie W et al. [The analysis of species identification and susceptibility testing of Mycobacterium abscessus]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262693
Kurosaki Y et al. [Two cases of pulmonary Mycobacterium avium complex disease with resistance to clarithromycin]. 2014 Kekkaku pmid:24979948
Iwanaga K and Carter ER Mycobacterium abscessus complex lung infection in a toddler with a tracheostomy. 2014 Pediatr. Pulmonol. pmid:23460506
Campanale M et al. Nickel free-diet enhances the Helicobacter pylori eradication rate: a pilot study. 2014 Dig. Dis. Sci. pmid:24595654
Schuhfried G et al. Gilles de la Tourette Syndrome caused by Mycoplasma pneumoniae successfully treated with macrolides. 2014 Klin Padiatr pmid:25153913
Svanström H et al. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. 2014 BMJ pmid:25139799
Giamarellos-Bourboulis EJ et al. Effect of clarithromycin in patients with suspected Gram-negative sepsis: results of a randomized controlled trial. 2014 J. Antimicrob. Chemother. pmid:24292991
Zhao Y and Hu ZY Physiologically based pharmacokinetic modelling and in vivo [I]/K(i) accurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate. 2014 Br. J. Pharmacol. pmid:24283665
Harvey E and Varatharaj A Round pneumonia. 2014 QJM pmid:23708793
Çiftci İH et al. Comparison of FISH, RFLP and agar dilution methods for testing clarithromycin resistance of Helicobacter pylori. 2014 Turk J Gastroenterol pmid:25910373
Oztürk K et al. Diagnosis of helicobacter pylori infection. 2014 Turk J Gastroenterol pmid:25141328
Kang BK et al. [New therapeutic strategies against Helicobacter pylori]. 2014 Korean J Gastroenterol pmid:24651587
Lee JY and Kim N [Future trends of Helicobacter pylori eradication therapy in Korea]. 2014 Korean J Gastroenterol pmid:24651589
Lee SH et al. The drug resistance profile of Mycobacterium abscessus group strains from Korea. 2014 Ann Lab Med pmid:24422193
Pathak V et al. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia. 2014 Ann Am Thorac Soc pmid:24460438
Jesus FP et al. In vitro synergism observed with azithromycin, clarithromycin, minocycline, or tigecycline in association with antifungal agents against Pythium insidiosum. 2014 Antimicrob. Agents Chemother. pmid:25001300
Wu JY et al. Evidence-based recommendations for successful Helicobacter pylori treatment. 2014 Expert Rev Gastroenterol Hepatol pmid:24410470
Sugamata R et al. Leucomycin A3, a 16-membered macrolide antibiotic, inhibits influenza A virus infection and disease progression. 2014 J. Antibiot. pmid:24496145
Díaz Cuevas Z et al. [Nodular skin lesions in a patient with rheumatoid arthritis under therapy with anti-tumor necrosis factor-α]. 2014 Med Clin (Barc) pmid:23877097
Jung YS et al. [Trends in the eradication rates of Helicobacter pylori infection in Daegu and Gyeongsangbuk-do, Korea: multicenter study over 13 years]. 2014 Korean J Gastroenterol pmid:24561694
Vanderpas J et al. Follow-up of Helicobacter pylori infection in children over two decades (1988-2007): persistence, relapse and acquisition rates. 2014 Epidemiol. Infect. pmid:23809783
Koh S et al. Visualization of the meibomian glands by means of noncontact mobile-type meibography (Meibopen) in a 16-year-old girl with unilateral marginal staphylococcal keratitis. 2014 J AAPOS pmid:24568999
Ke AB et al. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies. 2014 Clin. Pharmacol. Ther. pmid:24747234
Oğuz M and Mihçiokur H Environmental risk assessment of selected pharmaceuticals in Turkey. 2014 Environ. Toxicol. Pharmacol. pmid:24929476
Ghosh N et al. Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma. 2014 Am. J. Hematol. pmid:24723438
Gisbert JP et al. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection. 2014 Dig. Dis. Sci. pmid:24126798
Maurer FP et al. Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus. 2014 J. Antimicrob. Chemother. pmid:24500188
Tranos P et al. Bilateral diffuse iris atrophy after the use of oral clarithromycin. 2014 Cutan Ocul Toxicol pmid:23763291
Farley R et al. Antibiotics for bronchiolitis in children under two years of age. 2014 Cochrane Database Syst Rev pmid:25300167
Page SR and Yee KC Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin. 2014 Intern Med J pmid:25041770
Phillips RO et al. Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease. 2014 Antimicrob. Agents Chemother. pmid:24323473
McNicholl AG et al. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. 2014 Gut pmid:23665990
Rakici H et al. Comparison of levofloxacin- and moxifloxacin-based triple therapies with standard treatment in eradication of Helicobacter pylori as first-line therapy. 2014 Digestion pmid:25547786
Karamanolis GP et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Greece. 2014 Digestion pmid:25531953
Hemphill A et al. Treatment of echinococcosis: albendazole and mebendazole--what else? 2014 Parasite pmid:25526545
Kawai T et al. Changes in the first line Helicobacter pylori eradication rates using the triple therapy-a multicenter study in the Tokyo metropolitan area (Tokyo Helicobacter pylori study group). 2014 J. Gastroenterol. Hepatol. pmid:25521730
Srinarong C et al. Improved eradication rate of standard triple therapy by adding bismuth and probiotic supplement for Helicobacter pylori treatment in Thailand. 2014 Asian Pac. J. Cancer Prev. pmid:25520127
Wang B et al. Standard triple therapy for Helicobacter pylori infection in China: a meta-analysis. 2014 World J. Gastroenterol. pmid:25356059
Komiya K et al. Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease: a propensity score analysis. 2014 Int. J. Antimicrob. Agents pmid:24948577
Homma S et al. The successful management of respiratory complications with long-term, low-dose macrolide administration in pediatric heart transplant recipients. 2014 Int Heart J pmid:25297501
Renvoisé A et al. Significant difference in drug susceptibility distribution between Mycobacterium avium and Mycobacterium intracellulare. 2014 J. Clin. Microbiol. pmid:25274991
Tu S and Yang H [Progress in the treatment of Helicobacter pylori infection]. 2014 Zhong Nan Da Xue Xue Bao Yi Xue Ban pmid:25269503
Malfertheiner P and Selgrad M Helicobacter pylori. 2014 Curr. Opin. Gastroenterol. pmid:25268839
Ito Y et al. The influence of environmental exposure on the response to antimicrobial treatment in pulmonary Mycobacterial avium complex disease. 2014 BMC Infect. Dis. pmid:25266993
de Miguel-Martinez I et al. [Bacteriemia due to Mycobacterium canariasense in an oncohematological patient with a long-term central device]. 2014 Enferm. Infecc. Microbiol. Clin. pmid:25262854
Gui J et al. [Subspecies identification for Mycobacterium abscessus group]. 2014 Zhonghua Jie He He Hu Xi Za Zhi pmid:25262692
Higgins JW et al. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1. 2014 Drug Metab. Dispos. pmid:25106415
Boleda MR et al. Survey of the occurrence of pharmaceuticals in Spanish finished drinking waters. 2014 Environ Sci Pollut Res Int pmid:24756682
Nilsson MF and Webster WS Effects of macrolide antibiotics on rat embryonic heart function in vitro. 2014 Birth Defects Res. B Dev. Reprod. Toxicol. pmid:24753334
Peng YC et al. Clarithromycin modulates Helicobacter pylori-induced activation of nuclear factor-κB through classical and alternative pathways in gastric epithelial cells. 2014 Clin. Exp. Med. pmid:23129507
Parekh TM et al. Hypoglycemia after antimicrobial drug prescription for older patients using sulfonylureas. 2014 JAMA Intern Med pmid:25179404
Kutluk G et al. Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains? 2014 Eur J Gastroenterol Hepatol pmid:25171023
Higashi F et al. Additional treatment with clarithromycin reduces fever duration in patients with influenza. 2014 Respir Investig pmid:25169846
de Boer EM et al. [Antibiotic resistance of Helicobacter pylori: prevalence in one region in the southern Netherlands and implications for treatment]. 2014 Ned Tijdschr Geneeskd pmid:25159698
Wallace RJ et al. Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. 2014 Chest pmid:24457542
Molina-Infante J and Gisbert JP Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance. 2014 World J. Gastroenterol. pmid:25132750
Heo J et al. A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication. 2014 Dig Liver Dis pmid:25132282
Lebedeva MV et al. Clarithromycin as a chiral selector for enantioseparation of basic compounds in nonaqueous capillary electrophoresis. 2014 Electrophoresis pmid:25100556
Katayama M et al. Preliminary study of interaction of clarithromycin with tacrolimus in cats. 2014 J. Vet. Med. Sci. pmid:25099737
Teh X et al. Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur. 2014 PLoS ONE pmid:25003707
Lyons J et al. An unusual lung mass post stem cell transplantation. 2014 Transpl Infect Dis pmid:24995624
Lee JW et al. A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea. 2014 Scand. J. Gastroenterol. pmid:24988873
Rakici H et al. Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates. 2014 J Dig Dis pmid:24980811
Acosta CP et al. [Determination of single nucleotide mutations in the 23S rRNA gene of Helicobacter pylori related to clarithromycin resistance in a population from Cauca, Colombia]. 2014 Biomedica pmid:24968047
Lee JW et al. GenoType HelicoDR test in the determination of antimicrobial resistance of Helicobacter pylori in Korea. 2014 Scand. J. Gastroenterol. pmid:24957849
Raffaldi I et al. An atypical deep neck infection in a two-year-old child. 2014 Infez Med pmid:24955801
Oh DH et al. Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy. 2014 J. Gastroenterol. Hepatol. pmid:24955448
Patel K et al. Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity. 2014 Int J Pharm pmid:24954663
Vafaeimanesh J et al. Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients. 2014 Saudi J Kidney Dis Transpl pmid:24434382
Bonferoni MC et al. Ionic polymeric micelles based on chitosan and fatty acids and intended for wound healing. Comparison of linoleic and oleic acid. 2014 Eur J Pharm Biopharm pmid:24384070
Liu CP et al. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. 2014 Pulm Pharmacol Ther pmid:23518214
Philips RC et al. Mycobacterium fortuitum infection arising in a new tattoo. 2014 Dermatol. Online J. pmid:24945647
Pan-In P et al. Ethyl cellulose nanoparticles: clarithomycin encapsulation and eradication of H. pylori. 2014 Carbohydr Polym pmid:24815396
Ichihara A et al. Case of disseminated cutaneous Mycobacterium chelonae infection mimicking cutaneous vasculitis. 2014 J. Dermatol. pmid:24801916
Togami K et al. Involvement of intestinal permeability in the oral absorption of clarithromycin and telithromycin. 2014 Biopharm Drug Dispos pmid:24801141
Bernut A et al. In vivo assessment of drug efficacy against Mycobacterium abscessus using the embryonic zebrafish test system. 2014 Antimicrob. Agents Chemother. pmid:24798271
Adebisi AO and Conway BR Lectin-conjugated microspheres for eradication of Helicobacter pylori infection and interaction with mucus. 2014 Int J Pharm pmid:24792977
Jarand J and Field SK Embrace simplicity when treating lady windermere. 2014 Chest pmid:25091749
Bolhuis MS et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. 2014 Eur. Respir. J. pmid:24791826
Zhao LJ et al. Helicobacter pylori isolates from ethnic minority patients in Guangxi: resistance rates, mechanisms, and genotype. 2014 World J. Gastroenterol. pmid:24782630
Peretz A et al. Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults. 2014 J. Antibiot. pmid:24781955
Nishida T et al. Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan. 2014 World J. Gastroenterol. pmid:24764674
Zhou L et al. Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study. 2014 Chin. Med. J. pmid:24762588
Luo Q et al. [Clinical effect of clarithromycin therapy in patients with chronic rhinosinusitis]. 2014 Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi pmid:24742507
Trotti LM et al. Further experience using clarithromycin in patients with Kleine-Levin syndrome. 2014 J Clin Sleep Med pmid:24733995
Khalili N Sunny hypomania associated with clarithromycin: a case report. 2014 J Clin Psychopharmacol pmid:24717249
Onyekwere CA et al. Rabeprazole, clarithromycin, and amoxicillin Helicobacter pylori eradication therapy: report of an efficacy study. 2014 World J. Gastroenterol. pmid:24707145
Karaolia P et al. Reduction of clarithromycin and sulfamethoxazole-resistant Enterococcus by pilot-scale solar-driven Fenton oxidation. 2014 Sci. Total Environ. pmid:24012892
Rizzo A et al. Antimicrobial effect of natural polyphenols with or without antibiotics on Chlamydia pneumoniae infection in vitro. 2014 Microb. Drug Resist. pmid:23952319